2026-06-27T15:56:46Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/127512024-09-04T14:52:20Zcom_20.500.14352_14col_20.500.14352_15

00925njm 22002777a 4500 dc Bezerra Souza, Adriana author Fernández García, Raquel author Rodrigues, Gabriela F. author Bolas Fernández, Francisco author Dalastra Laurenti, Marcia author Passero, Luiz Felipe author Lalatsa, Aikaterini author Serrano López, Dolores Remedios author 2019-07-20 Leishmaniasis is a neglected tropical disease a_ecting more than 12 million people worldwide, which in its visceral clinical form (VL) is characterised by the accumulation of parasites in the liver and spleen, and can lead to death if not treated. Available treatments are not well tolerated due to severe adverse e_ects, need for parenteral administration and patient hospitalisation, and long duration of expensive treatments. These treatment realities justify the search for new e_ective drugs, repurposing existing licensed drugs towards safer and non-invasive cost-e_ective medicines for VL. In this work, we provide proof of concept studies of butenafine and butenafine self-nanoemulsifying drug delivery systems (B-SNEDDS) against Leishmania infantum. Liquid B-SNEDDS were optimised using design of experiments, and then were spray-dried onto porous colloidal silica carriers to produce solid-B-SNEDDS with enhanced flow properties and drug stability. Optimal liquid B-SNEDDS consisted of Butenafine:Capryol 90:Peceol:Labrasol (3:49.5:24.2:23.3 w/w), which were then sprayed-dried with Aerosil 200 with a final 1:2 (Aerosil:liquid B-SNEDDS w/w) ratio. Spray-dried particles exhibited near-maximal drug loading, while maintaining excellent powder flow properties (angle of repose <10_) and sustained release in acidic gastrointestinal media. Solid-B-SNEDDS demonstrated greater selectivity index against promastigotes and L. infantum-infected amastigotes than butenafine alone. Developed oral solid nanomedicines enable the non-invasive and safe administration of butenafine as a cost-e_ective and readily scalable repurposed medicine for VL. Bezerra Souza, A., Fernández García, R., Rodrigues, G. F. et al. «Repurposing Butenafine as An Oral Nanomedicine for Visceral Leishmaniasis». Pharmaceutics, vol. 11, n.o 7, julio de 2019, p. 353. DOI.org (Crossref), https://doi.org/10.3390/pharmaceutics11070353. 1999-4923 10.3390/pharmaceutics11070353 https://hdl.handle.net/20.500.14352/12751 https://doi.org/10.3390/pharmaceutics11070353 Repurposing Butenafine as An Oral Nanomedicine for Visceral Leishmaniasis